Abstract
Purpose of reviewRecurrent focal segmental glomerulosclerosis (FSGS) presents with nephrotic syndrome shortly after kidney transplantation. This review will overview the role of circulating permeability factors in disease pathogenesis and treatment options for recurrent FSGS.Recent findingsNovel circulating permeability factors have been identified in serum samples. Current research is focused on detection of permeability factors as a marker of treatment response. Furthermore, novel monoclonal antibodies are being utilized to further induce remission.SummaryPosttransplant recurrent FSGS can have a deleterious effect on allograft. Early detection of disease recurrence with prompt treatment is optimal for clinical remission. Plasmapheresis with anti-B cell therapy is considered the mainstay of treatment. Newer B cell therapies and detection of circulating factors in serum may help in providing targeted treatment in a subset of patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 61-66 |
| Number of pages | 6 |
| Journal | Current opinion in nephrology and hypertension |
| Volume | 33 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2024 |
Keywords
- focal segmental glomerulosclerosis
- kidney transplantation
- recurrent focal segmental glomerulosclerosis
ASJC Scopus subject areas
- Nephrology
- Internal Medicine